Quantitative mRNA expression analysis of selected genes in patients with early-stage hypothyroidism induced by treatment with iodine-131

Guo,Kun; Gao,Rui; Yu,Yan; Zhang,Weixiao; Yang,Yuxuan; Yang,Aimin

doi:10.3892/mmr.2015.4350

Quantitative mRNA expression analysis of selected genes in patients with early-stage hypothyroidism induced by treatment with iodine-131

Authors:
- Kun Guo
- Rui Gao
- Yan Yu
- Weixiao Zhang
- Yuxuan Yang
- Aimin Yang
View Affiliations

Affiliations: Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, P.R. China , Department of Public Health, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: September 23, 2015 https://doi.org/10.3892/mmr.2015.4350
Pages: 7673-7680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the molecular markers indicative of early-stage hypothyroidism induced by treatment with iodine-131, in order to assist in further investigations of radio iodine‑induced hypothyroidism. A total of 59 patients diagnosed with hyperthyroidism (male/female, 16/43; median age, 46.4 years) and 27 healthy subjects (male/female, 7/21; median age, 44.6 years) were included in the present study. All patients were treated with appropriate doses of iodine‑131 and, three months following treatment, the patients were subdivided into two groups: A group with early‑stage hypothyroidism symptoms, and a group with non‑early‑stage hypothyroidism, including euthyroid patients and patients remaining with hyperthyroidism. Tissue samples from the patients and healthy subjects were collected by fine needle biopsies, and the mRNA expression levels of B-cell lymphoma 2 (Bcl‑2), nuclear factor (NF)‑κB, Ku70, epidermal growth factor receptor (EGFR), early growth response 1 (Egr‑1), TP53 and ataxia telangiectasia mutated were analyzed using reverse transcription‑quantitative polymerase chain reaction prior to iodine‑131 treatment. The association of the variation of target genes with susceptibility to early‑stage hypothyroidism was analyzed. Compared with normal subjects, the mRNA expression levels of Ku70 (0.768, vs. 3.304, respectively; P<0.001) and EGFR (0.859, vs. 1.752, respectively; P<0.05) were significantly higher, whereas those of NF‑κB (0.884, vs. 0.578, respectively; P<0.05) and Bcl‑2 (1.235, vs. 0.834, respectively; P<0.05) were lower in the hyperthyroid patients. Following treatment with iodine‑131, 30 of the 59 (50.8%) patients with hyperthyroidism were diagnosed with early‑stage hypothyroidism, and in the early‑stage hypothyroidism group, the mRNA expression levels of Bcl‑2 were significantly decreased (P<0.05), whereas those of Egr‑1 (P<0.05) were significantly increased, compared with the non‑early‑stage hypothyroidism group. The association between the changes in the expression levles of Bcl‑2 and Egr‑1 and susceptibility to early‑stage hypothyroidism was supported by multivariate regression analysis. No significant changes in the expression levels of the other target genes were detected. The opposing changes in the mRNA expression levels of Bcl‑2 and Egr‑1 in patients with early‑stage hypothyroidism indicates their potential as prognostic markers of early-stage hypothyroidism induced by iodine-131 treatment.

View Figures

View References

1	Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, et al American Thyroid Association; American Association of Clinical Endocrinologists: Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 21:593–646. 2011. View Article : Google Scholar : PubMed/NCBI
2	Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, et al: The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf). 43:55–68. 1995. View Article : Google Scholar
3	Klein I and Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med. 344:501–509. 2001. View Article : Google Scholar : PubMed/NCBI
4	Effraimidis G and Wiersinga WM: Mechanisms in endocrinology: Autoimmune thyroid disease: Old and new players. Eur J Endocrinol. 170:R241–R252. 2014. View Article : Google Scholar : PubMed/NCBI
5	Solomon B, Glinoer D, Lagasse R and Wartofsky L: Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 70:1518–1524. 1990. View Article : Google Scholar : PubMed/NCBI
6	Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y and Izumi M: Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the united states. Thyroid. 1:129–135. 1991. View Article : Google Scholar
7	Kraft O: Hypothyroidism and radioiodine therapy. Cancer Biother Radiopharm. 22:261–267. 2007. View Article : Google Scholar : PubMed/NCBI
8	Berg GE, Michanek AM, Holmberg EC and Fink M: Iodine-131 treatment of hyperthyroidism: Significance of effective half-life measurements. J Nucl Med. 37:228–232. 1996.PubMed/NCBI
9	Catargi B, Leprat F, Guyot M, Valli N, Ducassou D and Tabarin A: Optimized radioiodine therapy of Graves' disease: Analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 141:117–121. 1999. View Article : Google Scholar : PubMed/NCBI
10	de Jong JA, Verkooijen HM, Valk GD, Zelissen PM and de Keizer B: High failure rates after 131I therapy in graves hyperthyroidism patients with large thyroid volumes, high iodine uptake and high iodine turnover. Clin Nucl Med. 38:401–406. 2013. View Article : Google Scholar : PubMed/NCBI
11	Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD and Rosser CJ: Downregulation of BCL-2 induces downregulation of carbonicanhydrase IX, vascular endothelial growth factor and pAkt and induces radiation sensitization. Urology. 70:832–837. 2007. View Article : Google Scholar : PubMed/NCBI
12	Schneider J, Illig T, Rosenberger A, Bickeböller H and Wichmann HE: Detection of atm gene mutations in young lung cancer patients: A population-based control study. Arch Med Res. 39:226–231. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kiyozuka M, Akimoto T, Fukutome M, Motegi A and Mitsuhashi N: Radiation-induced dimer formation of EGFR: Implications for the radiosensitizing effect of cetuximab. Anticancer Res. 33:4337–4346. 2013.PubMed/NCBI
14	Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:2884–2890. 1999.PubMed/NCBI
15	Vera-Badillo FE, Al-Mubarak M, Templeton AJ and Amir E: Benefit and harms of new anti-cancer drugs. Curr Oncol Rep. 15:270–275. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ahmed MM, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Wood DP Jr, Sells SF, Mohiuddin M and Rangnekar VM: EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem. 271:29231–29237. 1996. View Article : Google Scholar : PubMed/NCBI
17	Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, Bedford MT, Prichard J, Mohiuddin M and Ahmed MM: EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene. 28:1121–1131. 2009. View Article : Google Scholar : PubMed/NCBI
18	Marinelli LD, Quimby EH and Hine GJ: Dosage determination with radioactive isotopes. Nucleonics. 2:561948.PubMed/NCBI
19	Zhang W, Gao R, Yu Y, Guo K, Hou P, Yu M, Liu Y and Yang A: Iodine-131 induces apoptosis in HTori-3 human thyrocyte cell line and G2/M phase arrest in a p53-independent pathway. Mol Med Rep. 11:3148–3154. 2015.
20	Erem C, Kandemir N, Hacihasanoglu A, Ersöz HO, Ukinc K and Kocak M: Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 25:55–60. 2004. View Article : Google Scholar : PubMed/NCBI
21	Vaidya B, Williams GR, Abraham P and Pearce SH: Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf). 68:814–820. 2008. View Article : Google Scholar
22	Nygarrd B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P and Hansen JM: Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med. 238:491–497. 1995. View Article : Google Scholar
23	Sridama V, McCormick M, Kaplan EL, Fauchet R and DeGroot LJ: Long-term follow-up study of compensated low-dose 13lI therapy for Graves' disease. N Engl J Med. 311:426–432. 1984. View Article : Google Scholar : PubMed/NCBI
24	Farkasova T, Gurska S, Witkovsky V and Gabelova A: Significance of amino acid substitution variants of DNA repair genes in radiosusceptibility of cervical cancer patients; a pilot study. Neoplasma. 55:330–337. 2008.PubMed/NCBI
25	Krempler A, Deckbar D, Jeggo PA and Löbrich M: An imperfect G2M checkpoint contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle. 6:1682–1686. 2007. View Article : Google Scholar : PubMed/NCBI
26	Darzynkiewicz Z, Zhao H, Halicka HD, Rybak P, Dobrucki J and Wlodkowic D: DNA damage signaling assessed in individual cells in relation to the cell cycle phase and induction of apoptosis. Crit Rev Clin Lab Sci. 49:199–217. 2012. View Article : Google Scholar : PubMed/NCBI
27	Mimori T, Akizuki M, Yamagata H, Inada S, Yoshida S and Homma M: Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest. 68:611–620. 1981. View Article : Google Scholar : PubMed/NCBI
28	Dobbs TA, Tainer JA and Lees-Miller SP: A structural model for regulation of NHEJ by DNA-PKcs autophosphorylation. DNA Repair (Amst). 9:1307–1314. 2010. View Article : Google Scholar
29	Helmink BA and Sleckman BP: The response to and repair of RAG-mediated DNA double-strand breaks. Annu Rev Immunol. 30:175–202. 2012. View Article : Google Scholar : PubMed/NCBI
30	Otsuka K and Ochiya T: Genetic networks lead and follow tumor development: microRNA regulation of cell cycle and apoptosis in the p53 pathways. Biomed Res Int. 2014:7497242014. View Article : Google Scholar : PubMed/NCBI
31	Weixiao Z, Rui G, Yan Y, Kun G, Peng H, Yan L and Mingqi Y: Iodine-131 induces apoptosis in the HTori 3 cell line and G2/M arrest in a p53-independent pathway. Mol Med Rep. 11:3148–3154. 2015.
32	Kasai K, Kuroda H, Hashigami Y, Ishikawa M, Nakamura T and Shimoda SI: Specific epidermal growth factor receptors on porcine and human thyroid membranes. Horm Metab Res. 17:592–594. 1985. View Article : Google Scholar : PubMed/NCBI
33	Kanamori A, Abe Y, Yajima Y, Manabe Y and Ito K: Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J Clin Endocrinol Metab. 68:899–903. 1989. View Article : Google Scholar : PubMed/NCBI
34	Saller B, Stapfer G, Bein B, Hoermann R, Spelsberg F and Mann K: Increased binding capacity of receptors for the epidermal growth factor in benign thyroid nodules and thyroid malignancies. Clin Investig. 71:898–902. 1993. View Article : Google Scholar : PubMed/NCBI
35	Westermark K, Karlsson FA and Westermark B: Epidermal growth factor modulates thyroid growth and function in culture. Endocrinology. 112:1680–1686. 1983. View Article : Google Scholar : PubMed/NCBI
36	Mizukami Y, Nonomura A, Michigishi T, Yokoyama K, Noguchi M, Hashimoto T, Nakamura S and Matsubara F: Immunohistochemical demonstration of epidermal growth-factor receptors in normal, benign and malignant thyroid tissues. Int J Oncol. 1:331–335. 1992.PubMed/NCBI
37	Marti U, Ruchti C, Kämpf J, Thomas GA, Williams ED, Peter HJ, Gerber H and Bürgi U: Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid. 11:137–145. 2001. View Article : Google Scholar : PubMed/NCBI
38	Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y and Kumar A: Nuclear transcription factor NF-kappa B: Role in biology and medicine. Indian J Exp Biol. 42:341–353. 2004.PubMed/NCBI
39	Nandakumar DN, Koner BC, Vinayagamoorthi R, Nanda N, Negi VS, Goswami K, Bobby Z and Hamide A: Activation of NF-kappaB in lymphocytes and increase in serum immunoglobulin in hyperthyroidism: Possible role of oxidative stress. Immunobiology. 213:409–415. 2008. View Article : Google Scholar : PubMed/NCBI
40	Vinayagamoorthi R, Koner BC, Kavitha S, Nandakumar DN, Padma Priya P and Goswami K: Potentiation of humoral immune response and activation of NF-kappaB pathway in lymphocytes in experimentally induced hyperthyroid rats. Cell Immunol. 238:56–60. 2005. View Article : Google Scholar
41	Kumar A, Sinha RA, Tiwari M, Singh R, Koji T, Manhas N, Rastogi L, Pal L, Shrivastava A, Sahu RP and Godbole MM: Hyperthyroidism induces apoptosis in rat liver through activation of death receptor-mediated pathways. J Hepatol. 46:888–898. 2007. View Article : Google Scholar : PubMed/NCBI
42	Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 159:387–397. 2001. View Article : Google Scholar : PubMed/NCBI
43	Mattson MP and Camandola S: NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 107:247–254. 2001. View Article : Google Scholar : PubMed/NCBI
44	Chen C, Edelstein LC and Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol. 20:2687–2695. 2000. View Article : Google Scholar : PubMed/NCBI
45	Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar
46	Klatka M, Grywalska E, Polak A and Roliński J: Impact of treatment with methimazole on the Bcl-2 expression in CD8+ peripheral blood lymphocytes in children with Graves' disease. Ann Agric Environ Med. 20:884–888. 2013.PubMed/NCBI
47	Giriş M, Erbil Y, Depboylu B, Mete O, Türkoğlu U, Abbasoğlu SD and Uysal M: Heme oxygenase-1 prevents hyperthyroidism induced hepatic damage via an antioxidant and antiapoptotic pathway. J Surg Res. 164:266–275. 2010. View Article : Google Scholar